Company intelligence / Profile preview

Cellerator

Lyngby, Capital Region of Denmark, Denmark

Ownership: Private
Development stage: Other

Overview

Cellerator is a Novo Nordisk Foundation–owned GMP cell therapy development and manufacturing company at the Technical University of Denmark (DTU), created to scale and industrialize cell therapies that have shown efficacy in animal models and to manufacture them for phase I/II clinical trials for multiple chronic diseases; it does not run its own therapeutic pipeline but supports external academic, biotech and pharma programs.

Therapeutic areas: NephrologyEndocrinologyCardiovascularNeurologyOncology
Modalities: Cell therapy
Industry: Contract Manufacturing Organization

Partnerships

reNEW – Novo Nordisk Foundation Center for Stem Cell Medicine

Beyond the preview

Go deeper on Cellerator.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellerator.

Explore the full profile